Generic drug
Paclitaxel price, strengths & recalls
Paclitaxel has no weekly pharmacy acquisition cost. 19 manufacturers make it. It has 7 recalls on record, none ongoing. Its official label last changed on January 5, 2026.
GenericPaclitaxel price by strength
What pharmacies pay for each strength and form this week, for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 6 mg/mL injection | Not priced this week | |||
| 100 mg injection | Not priced this week | |||
Supply status: shortages & recalls
Recalls
Showing the 6 most relevant of 7 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Paclitaxel
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) safely and effectively. See full prescribing information for PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND).PACLITAXEL protein-bound particles for injectable suspension(albumin-bound), for intravenous useInitial U.S. Approval: 2005
WARNING: SEVERE MYELOSUPPRESSION
Do not administer Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) therapy to patients who have baseline neutrophil counts of less than 1,500 cells/mm3. [see Contraindications (4)].
Monitor for neutropenia, which may be severe and result in infection or sepsis, [see Warnings and Precautions (5.1, 5.3)].
Perform frequent complete blood cell counts on all patients receiving Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) [see Contraindications (4), Warnings and Precautions (5.1, 5.3)].
WARNING: SEVERE MYELOSUPPRESSION
See full prescribing information for complete boxed warning.
Do not administer Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm3. (4)
Monitor for neutropenia, which may be severe and result in infection or sepsis. (5.1, 5.3)
Perform frequent complete blood cell counts on all patients receiving Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound). (5.1, 5.3)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA216338 · Teva Pharms Inc
- First approved
- May 11, 2023 (3 years ago)
- Latest approved change
- November 21, 2023
- Approved label
- PDF, Nov 22, 2023
- Generic makers
- 10 approved generic applications on the market
Paclitaxel questions
Is paclitaxel in shortage?
No shortage is reported for paclitaxel right now. We check the national shortage list every day.
Has paclitaxel been recalled?
7 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the paclitaxel label last change?
The official label was last updated on January 5, 2026 (version 4). See what changed.
Talk about paclitaxel
No comments yet. Questions, tips, what worked for you - start the conversation.